Christopher Peetz Mirum Pharmaceuticals, Inc. (MIRM) insider trading activity

Christopher Peetz is CHIEF EXECUTIVE OFFICER of Mirum Pharmaceuticals, Inc.. Currently has a direct ownership of 115,920 shares of MIRM, which is worth approximately $5.04 Million. The most recent transaction as insider was on Mar 03, 2025, when has been sold 40,000 shares (Common Stock) at a price of $46.9 per share, resulting in proceeds of $1,876,000. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 116K

8.62% 3M change

11.34% 12M change

Total Value Held $5.04 Million

Christopher Peetz Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Mar 03 2025	SELL Open market or private sale	$1,876,000 $46.9 p/Share	40,000 Reduced 25.65%	115,920 Common Stock
Mar 03 2025	BUY Exercise of conversion of derivative security	$117,600 $2.94 p/Share	40,000 Added 20.42%	155,920 Common Stock
Feb 03 2025	SELL Open market or private sale	$438,898 $48.22 p/Share	9,102 Reduced 7.28%	115,920 Common Stock
Jan 24 2025	SELL Open market or private sale	$327,629 $47.92 p/Share	6,837 Reduced 5.19%	125,022 Common Stock
Jan 23 2025	BUY Exercise of conversion of derivative security	-	12,500 Added 8.66%	131,859 Common Stock
Jan 07 2025	SELL Open market or private sale	$320,678 $42.82 p/Share	7,489 Reduced 5.9%	119,359 Common Stock
Nov 08 2024	BUY Grant, award, or other acquisition	$1,368 $21.05 p/Share	65 Added 0.05%	126,848 Common Stock
Jul 23 2024	BUY Exercise of conversion of derivative security	$99,998 $2.94 p/Share	34,013 Added 21.15%	126,783 Common Stock
May 10 2024	BUY Grant, award, or other acquisition	$17,197 $21.05 p/Share	817 Added 0.87%	92,770 Common Stock
Feb 02 2024	SELL Open market or private sale	$157,480 $26.19 p/Share	6,013 Reduced 5.46%	104,112 Common Stock
Jan 08 2024	SELL Open market or private sale	$146,008 $28.03 p/Share	5,209 Reduced 4.52%	110,125 Common Stock
Jul 03 2023	SELL Open market or private sale	$141,023 $25.65 p/Share	5,498 Reduced 4.55%	115,334 Common Stock
May 10 2023	BUY Grant, award, or other acquisition	$21,251 $16.92 p/Share	1,256 Added 1.03%	120,832 Common Stock
Jan 31 2023	BUY Grant, award, or other acquisition	-	50,000 Added 29.49%	119,576 Common Stock
Jan 09 2023	SELL Open market or private sale	$106,378 $20.62 p/Share	5,159 Reduced 5.31%	91,953 Common Stock
Nov 10 2022	BUY Grant, award, or other acquisition	$835 $17.05 p/Share	49 Added 0.07%	69,576 Common Stock
May 10 2022	BUY Grant, award, or other acquisition	$20,355 $13.57 p/Share	1,500 Added 2.11%	69,527 Common Stock
Jan 06 2022	BUY Grant, award, or other acquisition	-	40,000 Added 37.03%	68,027 Common Stock
Nov 24 2021	BUY Open market or private purchase	$100,800 $14.4 p/Share	7,000 Added 19.98%	28,027 Common Stock
Oct 01 2021	SELL Open market or private sale	$70,723 $19.26 p/Share	3,672 Reduced 14.87%	21,027 Common Stock
Sep 29 2021	BUY Grant, award, or other acquisition	-	21,875 Added 46.97%	24,699 Common Stock
May 10 2021	BUY Grant, award, or other acquisition	$21,243 $14.62 p/Share	1,453 Added 33.97%	2,824 Common Stock
Nov 10 2020	BUY Grant, award, or other acquisition	$20,935 $15.27 p/Share	1,371 Added 50.0%	1,371 Common Stock

Also insider at

ALPN

ALPINE IMMUNE SCIENCES, INC. Healthcare

Director